Factor VIII products in haemophilia A: one size fits all?

References
1 Mannucci PM, Tuddenham EG. The haemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-1779.
2 Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with haemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
3 Gouw SC, van den Berg HM, Fischer K. et al. Intensity of factor VIII treatment and inhibitor development in children with severe haemophilia A: the RODIN study. Blood 2013; 121: 4046-4055.
4 Xi M, Makris M, Marcucci M. et al. Inhibitor development in previously treated haemophilia A patients: a systematic review, meta-analysis, and meta-regression. J Thromb Haemost 2013; 11: 1655-1662.
5 Santagostino E, Mancuso ME, Rocino A. et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-427.
6 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 09: 418-435.
7 Goudemand J, Laurian Y, Calvez T. Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol 2006; 13: 316-322.
8 Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-6362.
9 Hironaka T, Furukawa K, Esmon PC. et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992; 267: 8012-8020.
10 Grancha S, Navajas R, Maranon C. et al. Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates. Haemophilia 2011; 17: 709-710.
11 Dasgupta S, Repesse Y, Bayry J. et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-612.
12 Qadura M, Waters B, Burnett E. et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in haemophilia A mice. Blood 2009; 114: 871-880.
13 Ghio M, Contini P, Ottonello L. et al. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost 2003; 89: 365-373.
14 Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat haemophilia. Blood 2012; 119: 4108-4114.
15 Marcucci M, Mancuso ME, Santagostino E, et al. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost 2015; 113: 958-967.
16 Mannucci PM, Gringeri A, Peyvandi F. et al. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasmaproduct exposed toddlers). Haemophilia 2007; 13 (Suppl. 05) 65-68.
17 Gouw SC, van der Bom JG, Ljung R. et al. Factor VIII products and inhibitor development in severe haemophilia A. N Engl J Med 2013; 368: 231-239.
18 Iorio A, Skinner MW, Makris M. Factor VIII products and inhibitors in severe haemophilia A. N Engl J Med 2013; 368: 1456.
19 Kessler CM, Iorio A. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia 2013; 19: 351-354.
20 Calvez T, Chambost H, Claeyssens-Donadel S. et al Recombinant factor VIII products and inhibitor development in previously untreated boys with severe haemophilia A. Blood 2014; 124: 3398-3408.
21 Collins PW, Palmer BP, Chalmers EA. et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe haemophilia A, 2000–2011. Blood 2014; 124: 3389-3397.
22 Fischer K, Lassila R, Peyvandi F. et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113: 968-975.